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Abstract LUHMES cells, a recently established line of
immortalized embryonic mesencephalic cells, are the novel
in vitro model for studying Parkinson’s disease (PD) and
dopaminergic neuron biology. Phosphoglyceromutase 5
(PGAM5) is a mitochondrial protein involved in mi-
tophagy, mitochondria dynamics, and other processes im-
portant for PD pathogenesis. We tested the impact of
lentiviral overexpression of PGAM5 protein in LUHMES
cells on their differentiation and expression of 84 PD-re-
lated genes. LUHMES cells were transduced with PGAM5
or mock and treated with 100 lM 6-hydroxydopamine (6-
OHDA), a model PD neurotoxin. Real-Time PCR analysis
revealed that the treatment with 6-OHDA-induced changes
in expression of 44 PD-related genes. PGAM5 transduction
alone did not cause alternations in PD-related genes ex-
pression, nor it affected changes in gene expression me-
diated by 6-OHDA. The 6-OHDA-induced PD-related gene
expression profile of LUHMES cells is presented for the
first time and widely discussed.
Keywords Parkinson’s disease  Gene expression 
6-hydroxydopamine  LUHMES cells  PGAM5
Introduction
Parkinson‘s disease (PD) is the second most common
neurodegenerative disorder affecting mainly elderly peo-
ple. Till know, the detailed mechanism responsible for its
development remains unknown. The presently used thera-
pies are mainly symptomatic and alleviate only a part of
the symptoms that dramatically deteriorate the quality of
life of the patients. Taking to account the aging of the
population of many developed countries and enormous
socio-economical burden caused by PD, research regarding
the disease are considered as one of the main healthcare
priorities for the society (Dexter and Jenner 2013).
This study was aimed at evaluating the effects of phos-
phoglyceromutase 5 (PGAM5) overexpression in the cellu-
lar model of Parkinson‘s disease, 6-hydroxydopamine (6-
OHDA)-treated differentiated human embryonic mesen-
cephalic cells of the Lund Human Mesencephalic
(LUHMES) cell line. PGAM5 is a recently discovered mi-
tochondrial protein that may be strongly implicated in the
molecular processes responsible for the development of PD.
It was discovered as a regulator of the NRF2/KEAP1
pathway which is the main pathway responsible for trig-
gering transcription of a battery of antioxidant and pro-
survival genes in response to oxidative and electrophile
stressors (Lo and Hannink 2008; Venugopal and Jaiswal
1996). The NRF2/KEAP1 pathway is responsible for the
alleviation of the effects of PD model toxins, both in vitro
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and in vivo (Chen et al. 2009; Cuadrado et al. 2009; Lee
et al. 2003; Shin 2014). Moreover, the neuroprotective ef-
fects of the so-called ‘‘chemopreventive natural dietary
compounds’’, such as curcumin, resveratrol, or sulforaphan,
are also mediated by the NRF2/KEAP1 signaling pathway.
PGAM5 was found to bind the antiapoptic protein Bcl-xL
and regulate its KEAP1-dependent ubiquitination and sub-
sequent degradation (Lo and Hannink 2006). On the other
hand, PGAM5 itself is a KEAP1 target and tethers the whole
NRF2-KEAP1 complex to the mitochondrion. Silencing the
PGAM5 increased the NRF2-dependent transcription in
HeLa cells (Lo and Hannink 2008). It is plausible to assume
that PGAM5 might be responsible for the fine tuning of the
NRF2/KEAP1-dependent apoptic or survival response dur-
ing oxidative stress (Stepkowski and Kruszewski 2011). It
was recently shown that PGAM5 indirectly mediated Bcl-xL
degradation in irradiated prostate cancer cells and this pro-
cess was responsible for their radiosensitization by
parthenolide. Interestingly, in normal cells the same com-
pound protected against cell death by activating NRF2-de-
pendent transcription (Xu et al. 2013).
PGAM5 is also responsible for dephosphorylating and
activating ASK1, a higher order MAP kinase responsible
for induction of neuronal apoptosis via p38- JNK axis in
6-OHDA and 1-methyl-4-phenyl-1,2,3,6-tetrahydropy-
ridine (MPTP) models of PD (Ouyang and Shen 2006;
Takeda et al. 2009).
Finally, the importance of PGAM5 in mechanisms in-
volved in the development of PD was directly shown by Lu
et al. (2014), who found out that knockout of PGAM5 in
mouse cause a Parkinson‘s like movement disorder. This
pathogenic state was caused by the impairment of PINK1-
mediated mitophagy. The importance of PGAM5 in
PINK1/PARKIN-mediated mitophagy is also well sup-
ported by the previous in vitro studies (Sekine et al. 2012).
In this work, we used one of the most advanced in vitro
models of PD, namely differentiated LUHMES cells
treated with 6-OHDA (Lotharius et al. 2005; Schildknecht
et al. 2009). Unlike commonly used neuroblastoma cell
lines: SH-SY5Y or BE2-M17, LUHMES cells differen-
tiation is imprinted intrinsically rather than induced by
external factors, e.g., retinoic acid. The LUHMES cells are
kept in undifferentiated, proliferating stage by the expres-
sion of v-myc oncogene under control of Tet element
promoter that is silenced in the presence of tetracyclin.
Addition of the antibiotic and ablation of the fibroblast
growth factor from the medium lead to differentiation of
the cells into post-mitotic neurons phenotypically similar to
mature human dopaminergic neurons. 6-OHDA is a pro-
oxidative neurotoxin commonly used to model PD in ro-
dents. The intrastriatal administration of 6-OHDA in ro-
dents creates pathological events similar to human PD:
formation of aggregated alpha synuclein bodies,
proteasome inhibition, increased ubiquitination, nitration
and oxidation of proteins, gluthathione depletion, and
caspase 3 cleavage (Blesa et al. 2012). 6-OHDA-mediated
effects are not dependent on a direct inhibition of mito-
chondrial electron transport chain, but rather by the early
oxidative stress events that can be alleviated by the action
of NRF2/KEAP1 pathway, and therefore possibly modified
by alternating levels of PGAM5 (Cao et al. 2005). To find
out whether increased cellular abundance of PGAM5 pro-
tein change the effects of 6-OHDA exposure, we analyzed




LUHMES cells were grown in monolyer on NunclonDTM
cell culture flasks coated with poly-L-ornithine (50 lg/mL)
and human plasma fibronectin (1 lg/mL) (Sigma-Aldrich).
Filter sterilized poly-L-ornithine was mixed with fi-
bronectin, poured directly to the culture flasks (1 mL per
10 cm2) and left overnight at 37 C. The coating mixture
was then aspirated and the flasks were dried in the laminar
hood. Freshly coated flasks were used in each experiment.
Undifferentiated, proliferating cells were grown in Ad-
vanced DMEM/F-12 medium (Life Technologies) supple-
mented with N-1 supplement (Sigma-Aldrich, N6530),
basic fibroblast growth factor (bFGF) (Life Technologies)
and 2 mM L-glutamine. Differentiation was conducted ac-
cording to the previously established two-step protocol
(Scholz et al. 2011). Briefly, when cells reached 70 %
confluency medium was changed to a differentiation
medium containing 1 lg/mL tetracycline instead of bFGF.
On the next day (attributed as Day 2 of differentiation)
cells were trypsinized and seeded to the new flasks to
create a monolayer of separated differentiated cells without
visible clumps of unequally differentiated cells. Cells were
differentiated for 7 days before performing the final
experiment.
Lentiviral Transduction
Lentiviral plasmids were designed in the Centre for Ra-
diobiology and Biological Dosimetry to allow simultane-
ous expression of mitochondrially targeted DsRed2 and
long (289 amino acids) isoform of PGAM5
(CCDS53845.1) (further referred as PGAM5_L). Two
lentiviral constructs built on the pLV.Des2d.P_mito-
DsRed2 backbone were used in this study: PGAM5_L
cDNA plasmid and control mock plasmid containing MCS
and 3* FLAG sequence instead of PGAM5_L sequence.
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Both plasmids contained mtDsRed2 under the control of P1
promoter. PGAM5_L transcription was driven by the EF1
alpha promoter. The detailed maps of the viral vectors used
in this study are provided as supplementary material
(Supplementary Fig. 1). Lentiviruses packaging was out-
sourced (CYAGEN biosciences). On the first day of
LUHMES cells differentiation lentiviral particles were
added to the differentiation medium supplemented with
4 lg/mL Polybrene (106 viral particles per 1 mL). After
overnight transduction medium was removed and the cells
were subcultured into 21 cm2 flasks for further differen-
tiation for 6 days.
6-Hydroxydopamine Treatment
6-Hydroxydopamine hydrochloride (Sigma-Aldrich H4381)
was dissolved in 1 % ascorbic acid before every experiment
and protected from light. Fresh 6-OHDA solution was added
directly to culture medium for 6 h, to achieve the final
concentration 100 lM. Control cells were treated with the
appropriate vehicle buffer.
Microscopy Imaging
All pictures were taken with NIKON A1 fluorescence
microscope equipped with NIS ELEMENTS software.
NIKON 209 and 409 plan fluor objectives were used.
Live cell imaging was done with the use of Hoffman
modulation contrast, which is compatible with plastic cell
culture dishes. Nuclei were stained with Hoechst 33342 in
concentration of 2 lg/mL. To visualize neurite net, we
used a lipofilic dye, Dil Stain (1,10-dioctadecyl-3,3,30,30-
tetramethylindocarbocyanine perchlorate, Molecular
Probes).
RNA Isolation, Reverse Transcription, and Real-
Time PCR
Total RNA was extracted from the cell pellets using
ReliaPrepTM mini prep system (Promega), according to the
manufacturer’s protocol. RNA concentration and purity
were assessed photometrically using A260/A280 ratio.
RNA integrity was tested by agarose gel electrophoresis.
700 ng of the total RNA were converted to cDNA using
Fig. 1 The morphology of differentiated LUHMES cells. Lipofilic dye DiL was used to visualize the neurites. Nuclei were stained with Hoechst
dye and cell bodies were observed in bright field with Hoffman modulation contrast. All pictures were taken at 940 magnitude
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RT2 First Strand Kit (SABiosciences). The cDNA was used
for the expression profiling by the Human Parkinson‘s RT2
Profiler PCR Array (SABiosciences, cat. no. PAHS-124 Z),
according to the manufacturer’s instructions. This array
allows for measurement of the expression of 84-genes,
directly or potentially related to the PD (involved in Parkin
pathway, cell adhesion, ubiquitin pathway, apoptosis, and
inflammation, mitochondria metabolism, neuronal signal-
ing, cytoskeletal organization, and genes related to the ion
transport). For detailed list of genes see the manufacturer
webpage, http://www.sabiosciences.com. cDNA amount
corresponding to 6.35 ng of the total RNA was used for a
single well reaction, to achieve an average Ct of 23.
Relative gene expression was calculated using the DDCt
method with HPRT1, GAPDH, and B2M genes, as the
reference controls. Calculations were done using RT2
Profiler PCR Array Data Analysis Template provided by
SABiosciences. Statistical differences were examined by
Student’s t test with p\ 0.02 considered to be statistically
significant. Overexpression of PGAM5_L mRNA was ad-
ditionally tested by Real-Time PCR using a Taqman
probe specific for all PGAM5 isoforms according to a
manufacturer protocol (Life Technologies).
Western Blot Analysis
The protein concentration was determined using the
Bradford method. 30 lg of cell lysates (1 % Nonidet
buffer) were boiled for 10 min at 60 C in Laemmli sample
buffer. After that samples were loaded on 12 % SDS-
PAGE polyacrylamide gel and separated. After protein
transfer to PVDF membranes (BioRad), membranes were
blocked for 1 h with 5 % milk at 4 C and incubated with
primary antibodies diluted in blocking solution overnight
(4 C). Primary antibodies (Abcam 126534) were then
detected with HRP-conjugated secondary antibodies and
chemiluminescence was triggered by Western Bright ECL
reagent (Advansta) as substrate, and recorded on CL-
XPosure films (Pierce). Blots and films were scanned.
Molecular weight of protein bands was estimated in com-
parison to BenchMark Prestained protein ladder
(Invitrogen).
Results
Differentiation and Morphology of Mature, Post-
mitotic Neurons is not Affected by PGAM5_L
Overexpression
LUHMES cells were transduced at the first day of differ-
entiation with efficiency around 90 %, as estimated by
DsRed2 fluorescence. Overexpression of PGAM5 long
isoform was confirmed by Real-Time PCR and Western
Blot. The PGAM5_L mRNA was 8 times more abundant in
transduced LUHMES cells (Fig. 2b). Antibody against
PGAM5_L protein detected two bands around 32 kDa,
which were identified as PGAM5 long isoform and the
product of its cleavage by PARL protease (Sekine et al.
2012; Wang et al. 2012). In PGAM5_L overexpressing
cells the PARL-proteolytic form was more abundant than
intact protein. Conversely, in mock-transduced cells the
protein band attributed to intact protein was more intense
than the band characteristic for proteolytic PGAM5 form.
Furthermore, an additional band around 28–30 kDa was
detected in lysates of PGAM5_L overexpressing cells
suggesting the existence of an unknown smaller proteolytic
form (Fig. 2a).
Daily live cell imaging revealed that neither PGAM5_L
overexpression nor introduction of mtDsRed2 had any effect
on LUHMES cells differentiation or cell morphology. Both,
mtDsRed2 transduced (mock transduction) and PGAM5_L
overexpressing cells (mtDsRed2 ? PGAM5_L) uniformly
changed their phenotype to typical neuronal shape (Figs. 1,
3). We also observed no differences when we compared the
pattern of wild type cells differentiation with transductants
differentiation (data not shown). Neurite outgrowth started
to be visible at the third day of differentiation and after
5 day cells created a highly interconnected and multi-bran-
ched ‘‘neuronal net’’ as described by a previously estab-
lished protocol (Scholz et al. 2011).
6-OHDA Treatment, But not the PGAM5_L
Overexpression, cause Profound Changes
in the Expression of PD-Related Genes
We assayed the expression of 84 genes directly or poten-
tially involved in PD etiology. All the genes included in the
analysis are connected with PD development or their ex-
pression changed in various animal models of PD.
The analysis revealed no statistically significant differ-
ences in PD-related gene expression between the mock
transduced and PGAM5_L overexpressing cells. Conse-
quently, only small, statistically not significant changes in
gene expression were observed between mock transduced
and PGAM5_L overexpressing cells treated with 6-OHDA.
Nevertheless, the treatment of LUHMES cells with
6-OHDA significantly affected PD-related genes expres-
sion. As PGAM5 overexpression did not affect 6-OHDA-
induced gene expression, to calculate 6-OHDA-induced
gene expression changes the results of both groups
(PGAM5 and mock transduced) were pooled to further
strengthen the statistical significance of fold regulation
levels.
Among 84 assayed genes, the expression of 44 changed
more than 20 % (p B 0.02), 11 were up-regulated and 33
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were down-regulated. Among those, the expression of 20
genes changed more than 200 % (p B 0.020) (Table 1).
Considering functional gene groups assayed, we did not
observe the gene expression changes in genes related to
inflammation. The most abundant gene expression changes
were observed for genes related to: mitochondria, ion
transport, cell adhesion, and interconnection/vesicle sig-
naling (Table 2).
Discussion
It was previously shown that PGAM5 regulates mitophagy
in response to mitochondria depolarizing agent CCCP or
hypoxia, by two distinct mechanisms (Sekine et al. 2012;
Wu et al. 2014). Very recently, Pgam5 knockout mice were
analyzed and PGAM5 role in mitophagy induction was
established in an animal model. Mice lacking Pgam5 gene
were characterized by a PD like movement disorder, which
is thought to be mediated by a dopaminergic neurons de-
generation due to an inefficient mitophagy (Lu et al. 2014).
Thus, it was of interest to elucidate whether PGAM5
overexpression would affect the action of the model PD-
inducing toxin, 6-OHDA.
While the Pgam5 deficiency resulted in the induction of
PD resembling disorder in knock out mice, over expression
of the protein in differentiated neurons (LUHMES cells)
did not change the gene expression of any of the tested 84
PD-related genes, neither in vehicle-treated control nor in
100 lM 6-OHDA-treated cells. It is plausible that PGAM5
post translation modifications are more important for me-
diating its biological role than its abundance or up-
regulation does not have as pronounced biological effects
as its knockdown.
mtDsRed2 was introduced into lentiviral plasmids to act
as a transduction control and to allow visualization of
mitochondria dynamics. Judging from the mtDsRed2
fluorescence, its expression was relatively low, but high
enough to act as a transduction efficiency control. We
hypothesize that this could have been caused by P1 pro-
moter silencing and/or promoter or protein coding se-
quence mutation. Nevertheless, low mtDsRed2 expression
was not consistent with change in the expression of
PGAM5, which was driven by the different promoter. Due
to limited resources and fact that weak mtDsRed2 ex-
pression is even beneficial because that strong mtDsRed2
expression might have interfered with biological effects of
PGAM5 overexpression, we have not further studied this
problem and used mtDsRed2 only as a transduction effi-
ciency control.
PINK1 and PARK2 (coding PARKIN E3 ubiquitin li-
gase) are one of the currently known 12 genes, whose
monogenic mutations are found in genomes of patients
suffering from early or juvenile onset PD (Bonifati 2014).
Those two genes work in a common signaling pathway
responsible for triggering selective autophagy of
Fig. 2 PGAM5 expression in
lentivirally transduced
LUHMES cells. a The
abundance of PGAM5_L
protein was analyzed by
Western Blot. b The
overexpression of PGAM5_L
mRNA was quantified in Real-
Time PCR. Error bars represent
SD of fold change calculated
from three independent
experiments
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Fig. 3 LUHMES cells morphology during differentiation is not
influenced by PGAM5 transduction. Pictures of LUHMES cells,
mock or PGAM5_L transduced, were taken in 920 magnitude in
Hoffman modulation contrast at third, fifth and seventh day of
differentiation. Same cells were analyzed for red fluorescence of
DsRed2 (the marker of transduction)
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Serine/arginine-rich splicing factor 7 SRSF7 9G8, AAG3, SFRS7 p\ 10-9 2,272407525
Adenomatous polyposis coli APC BTPS2, DP2, DP2.5, DP3, GS, PPP1R46 p\ 10-8 -3,515342822
Phosphatase and tensin homolog PTEN 10q23del, BZS, CWS1, DEC, GLM2, MHAM,
MMAC1, PTEN1, TEP1
p\ 10-8 -2,324764994
N-ethylmaleimide-sensitive factor NSF SKD2 p\ 10-7 -2,453703041
Cell division cycle 27 homolog (S.
cerevisiae)
CDC27 ANAPC3, APC3, CDC27Hs, D0S1430E,
D17S978E, HNUC, NUC2
p\ 10-7 -1,992708428
Cell division cycle 42 (GTP binding
protein, 25 kDa)
CDC42 CDC42Hs, G25 K p\ 10-7 -1,534069252
Ubiquitin-like modifier activating enzyme
1
UBA1 A1S9, A1S9T, A1ST, AMCX1, GXP1, POC20,
SMAX2, UBA1A, UBE1, UBE1X
p\ 10-7 -1,595294085
Cullin 2 CUL2 – p\ 10-6 -2,3082953
Optic atrophy 1 (autosomal dominant) OPA1 MGM1, NPG, NTG, largeG p\ 10-6 -1,780188065
Actin, beta ACTB BRWS1, PS1TP5BP1 p\ 10-6 -1,562033576
Vesicle-associated membrane protein 1
(synaptobrevin 1)
VAMP1 SYB1, VAMP-1 p\ 10-6 5,010440698
PTEN-induced putative kinase 1 PINK1 BRPK, PARK6 p\ 10-6 -1,507431572
Amyloid beta (A4) precursor protein APP AAA, ABETA, ABPP, AD1, APPI, CTFgamma,
CVAP, PN-II, PN2
p\ 10-6 -1,745533857
Reticulon 1 RTN1 NSP p\ 10-6 -1,502605119
Egl nine homolog 1 (C. elegans) EGLN1 C1orf12, ECYT3, HIF-PH2, HIFPH2, HPH-2,
HPH2, PHD2, SM20, ZMYND6
p\ 10-6 1,525649248
Heat shock 70 kDa protein 4 HSPA4 APG-2, HS24, P52, HSPH2, RY, hsp70, hsp70RY p\ 10-5 -2,832602738
G protein-coupled receptor 37 (endothelin
receptor type B-like)
GPR37 EDNRBL, PAELR, hET(B)R-LP p\ 10-5 -1,986643383
Ca ??-dependent secretion activator CADPS CADPS1, CAPS, CAPS1 p\ 10-5 -2,981895566
Caspase 3, apoptosis-related cysteine
peptidase
CASP3 CPP32, CPP32B, SCA-1 p\ 10-5 -2,03831021
Voltage-dependent anion channel 3 VDAC3 HD-VDAC3, VDAC-3 p\ 10-5 -1,494780659
Parkinson protein 2, E3 ubiquitin protein
ligase (parkin)
PARK2 AR-JP, LPRS2, PDJ, PRKN p\ 10-4 -2,369409925
S-phase kinase-associated protein 1 SKP1 EMC19, OCP-II, OCP2, SKP1A, TCEB1L, p19A p\ 10-4 -1,4349779
Synaptotagmin I SYT1 P65, SVP65, SYT p\ 10-4 -2,755530058
Parkinson protein 7 PARK7 DJ-1, DJ1, HEL-S-67p p\ 10-4 -1,575583282
Ataxin 3 ATXN3 AT3, ATX3, JOS, MJD, MJD1, RP11-529H20.5,
SCA3
p\ 10-4 -1,782955859
Glucan (1,4-alpha-), branching enzyme 1 GBE1 APBD, GBE, GSD4 p\ 10-3 -1,685484474
F-box protein 9 FBXO9 FBX9, NY-REN-57, VCIA1, dJ341E18.2 p\ 10-3 -1,530293431
Cadherin 8, type 2 CDH8 Nbla04261 p\ 10-3 2,737917368
Synuclein, alpha (non A4 component of
amyloid precursor)
SNCA NACP, PARK1, PARK4, PD1 p\ 10-3 -2,93448938
Synaptic vesicle glycoprotein 2B SV2B HsT19680 p\ 10-3 -2,272650385
Dopamine receptor D2 DRD2 D2DR, D2R p\ 10-3 1,520682705
Delta-like 1 homolog (Drosophila) DLK1 DLK, DLK-1, Delta1, FA1, PREF1, Pref-1,
ZOG, pG2
p\ 10-3 -2,493362532
Regulator of G-protein signaling 4 RGS4 RGP4, SCZD9 p\ 10-3 -1,823980398
S100 calcium binding protein B S100B NEF, S100, S100-B, S100beta p\ 10-3 5,504391369
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mitochondria and regulating mitochondria transport
(Pickrell and Youle 2015; Scarffe et al. 2014). The treat-
ment with 100 lM 6-OHDA caused down regulation of
two cytoprotective genes and members of the Parkin
complex: HPS70 and PARK7 (coding DJ-1 protein). The
HPS70 and DJ-1 proteins bind each other to regulate the
cellular defense mechanism linked to oxidative insults
(Moore et al. 2005). PARK7 is one of the five known genes
whose mutations have been linked to familial forms of PD.
DJ-1 is generally considered being cytoprotective, as it is
up-regulated during oxidative stress and it is able to rescue
cells from apoptosis in response to parkinsonian toxins
(Bonifati et al. 2003; Inden et al. 2006; Yokota et al. 2003).
In SH-SY5Y neuroblastoma cells DJ-1 is up-regulated in
response to 6-OHDA (Lev et al. 2008). Interestingly, in
LUHMES cells, we have observed a half-fold decrease in
DJ-1 expression (p\ 10-4) and almost 3-fold decrease in
HSPA4 (p\ 10-5). This may indicate that LUHMES cells
are more sensitive to oxidative insults. Moreover, PINK1
and alpha synuclein, other genes mutated in mendelian
forms of PD, were also down-regulated in LUHMES cells
in response to 6-OHDA. It seems that the observed down-
regulation of cytoprotective genes related to parkin com-
plex is accompanied by the pro-apoptic rather than pro-
survival effect. Indeed, we also observed the three-fold up-
regulation of the initiator caspase 8.
The most profound changes in gene expression were
observed for synaptobrevin 1 coded by VAMP1 gene (5-
fold up-regulation, p\ 10-6) and adenomatous polyposis
coli gene (3.5-fold down-regulation p\ 10-8).
The synaptobrevin 1 is a member of the family of
vesicle-associated membrane proteins (VAMPs) that are a
part of the SNARE complex involved in vesicle fusion
during synaptic signaling and autophagy (Shih et al. 2005).
Apart from VAMP1 up-regulation, we have observed the
6-OHDA-induced decrease in expression of three other
genes, whose protein products are directly related to sy-
naptic vesicle signaling: synaptotagmin (SYT1, -2.7-fold),
synaptic vesicle glycoprotein (SV2B,-2.2-fold) and calci-
um-dependent activator protein for secretion (CADPS,
-2.9-fold). All of those proteins are implicated in the
Ca2?-dependent exocytosis. Synaptobrevins are known to
be targeted and degraded by tetanospasmin and bo-
tulinum—neurotoxins produced by anaerobic pathogens
from Clostridium sp. (Binz et al. 2010). The serotypes of
those neurotoxins are highly specific toward particular
orthologues of VAMP proteins present in different regions
of the organism (Yamamoto et al. 2012). Brain orthologues
VAMP1 and VAMP2 are present in different regions of the
rat brain (Ferecsko´ et al. 2015; Raptis et al. 2005).
Mendieta et al. (2012) shown that C- terminal part of te-









CXXC finger protein 1 CXXC1 2410002I16Rik, 5830420C16Rik, CFP1, CGBP,
HsT2645, PCCX1, PHF18, SPP1, ZCGPC1,
hCGBP
p\ 10-3 1,54484259
Caspase 8, apoptosis-related cysteine
peptidase
CASP8 ALPS2B, CAP4, Casp-8, FLICE, MACH, MCH5 p\ 10-2 3,087237999
Aldehyde dehydrogenase 1 family,
member A1
ALDH1A1 ALDC, ALDH-E1, ALDH1, ALDH11, HEL-S-
53e, HEL12, PUMB1, RALDH1
p\ 10-2 2,151296669
Potassium inwardly-rectifying channel,
subfamily J, member 6
KCNJ6 BIR1, GIRK-2, GIRK2, KATP-2, KATP2,
KCNJ7, KIR3.2, hiGIRK2
p\ 10-2 -1,526711915
Trophoblast glycoprotein TPBG 5T4, 5T4AG, M6P1 p\ 10-2 2,045570763
Dopa decarboxylase (aromatic L-amino
acid decarboxylase)
DDC AADC p\ 10-2 -2,037636174
Caspase 1, apoptosis-related cysteine
peptidase (interleukin 1, beta,
convertase)
CASP1 ICE, IL1BC, P45 p\ 0,02 1,993516068
Neurofilament, light polypeptide NEFL CMT1F, CMT2E, NF-L, NF68, NFL p\ 0,02 -1,225922474
Transcription factor 7-like 2 (T cell
specific, HMG-box)
TCF7L2 TCF-4, TCF4 p\ 0,02 -1,462013976
Solute carrier family 18 (vesicular
monoamine), member 2
SLC18A2 SVAT, SVMT, VAT2, VMAT2 p\ 0,02 -1,390565564
Over expressed gene names are highlighted in italic font. Statistical differences were examined by Student’s t test with p\ 0.02 considered to be
statistically significant. Only statistically significant gene expression changes higher than 20 % are shown. The p values and fold regulation levels
were calculated from six experiments
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protected rats from motor symptoms of Parkinson’s disease
induced by 6-OHDA. On the other hand, a case study was
published describing severe parkinsonian symptoms ob-
served after tetanus vaccination (Reijneveld et al. 1997). In
view of our results, it is plausible that the neuroprotective
effects of tetanospasmin C-terminal fragment could be at
least partially mediated by its hydrolyzing activity against
VAMPs, as we found VAMP1 to be highly up-regulated in
response to 6-OHDA in LUHMES cells. Fine tuning of
VAMPs in different brain regions by the use of clostridium
toxins or their derivates may be in future a promising
therapeutical mechanism to treat neurological disorders.
Adenomatous polyposis coli gene (APC) is the second
gene, which expression profoundly changed in 6-OHDA-
treated LUHMES cells (3.5-fold down-regulation
p\ 10-8). This gene is mostly known for its tumor sup-
pressing activities, and its mutation is associated with
severe pre-malignant syndrome (Groden et al. 1991; Zhang
et al. 2010). There is scare evidence of APC implications in
Parkinson’s disease, but it was found to be indispensible
for the nicotine acetylcholine synapse assembly (Temburni
et al. 2004). Furthermore, nicotine is believed to have
neuroprotective role against PD, as various epidemiologic
studies showed that smokers less frequently developed PD
(Hernan et al. 2002; Tanaka et al. 2010).
The decrease in dopamine content in the central nervous
system is the main cause of motor symptoms of PD. Our
gene expression analysis was also focused on genes related
to dopaminergic signaling. We found that 6-OHDA caused
a two-fold decrease in the expression of DOPA decar-
boxylase, an enzyme which catalyzes a rate limiting step of
dopamine synthesis. This decrease was accompanied by the
50 % increase in the expression of dopamine receptor 2.
The increase in the expression of dopamine receptor 2 is
probably a part of the compensation mechanism of
dopaminergic neurons, as it has been shown that degen-
eration of striatal dopaminergic neurons is accompanied by
the compensation mechanisms that allow maintaining
dopamine concentrations at the unchanged levels (Golden
et al. 2013; Zigmond et al. 1990).
The treatment with 100 lM 6-OHDA led also to the 5.5-
fold increase in the expression of S100B gene. S100B is a
calcium binding peptide with plenty of known biological
implications. S100 peptide is implicated in regulation of
proliferation, differentiation, apoptosis, Ca2? homeostasis,
energy metabolism, inflammation, and migration/invasion
through interactions with a variety of target proteins in-
cluding enzymes, cytoskeletal subunits, receptors, tran-
scription factors, and nucleic acids (Donato et al. 2013).
S100B is a prototype biomarker for brain injuries including
Table 2 The functional groups of PD-related genes and their expression regulation in response to 6-OHDA
Functional gene
group
Genes belonging to the group and their expression regulation in response to 6-OHDA
Parkin complex HSPA4 (HSP70), PARK7, STUB1
Parkin Substrate ATXN2, ATXN3, GPR37, SYT11
Cell adhesion APC, APP, CDH8, FN1, NFASC, NRXN3, PTEN, TPBG.
Ubiquitination CDC27, CUL2, FBXO9, LRRK2, PAN2, PARK2, PINK1, SKP1, STUB1, UBB, UBA1, UBE2I, UBE2 K, UBE2L3,
UCHL1, USP34
Inflammation FN1, PRDX2, YWHAZ
Apoptosis APC, APP, CASP1 (ICE), CASP3, CASP8 (FLICE), CASP9, CUL2, MAPK9 (JNK2), PSEN2, PTEN, BDNF, CASP3,
NEFL, NR4A2 (NURR1), OPA1, PPID, PRDX2, PSEN2, SLC25A4, SNCA, TCF7L2, UBB, YWHAZ
Mitochondria CASP3, CASP7, CASP8 (FLICE), HSPA4 (HSP70), LRRK2, NEFL, OPA1, PARK7, PINK1, PTEN, SLC25A4, SNCA,
TH, UCHL1, VAMP1, VDAC3, YWHAZ
Synaptic Vesicles LRRK2, SEPT5, SV2B, SYNGR3, SYT1, SYT11, TH
Signal Transduction Dopaminergic: NSG1, DDC, DRD2, HTR2A, NR4A2 (NURR1), PARK2, PARK7, PINK1, SEPT5, SLC6A3, SNCA, TH
GABAergic: DRD2, GABBR2
MAP Kinase: APC, FGF13, MAPK9 (JNK2), PRDX2, RGS4
Notch: APP, PSEN2, SPEN
Cytoskeletal
organization
APC, CDC42, MAPT, NEFL, PARK2.
Ion transport ATP2B2, CADPS, CXXC1, DRD2, EGLN1, GBE1, GRIA3, HTR2A, KCNJ6, NSF, PSEN2, S100B, SRSF7, SLIT1,
SNCA, VDAC3
Transporters ATP2B2, GRIA3, SLC18A2, SLC6A3, SLC25A4, SV2B, SYT1, SYT11, VDAC3
Others ALDH1A1, BASP1, CHGB, DLK1, NCOA1, NTRK2, RTN1
Up-regulated genes shown in bold. Down-regulated genes shown in undeline. Tested genes whose expression was not changed are highlighted in
italic
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trauma and stroke. We found that in control cells the ex-
pression of S100B was very weak, while in 6-OHDA-
treated cells it increased to the levels that could be reliably
quantified by RT-PCR. S100B is expressed and released by
astro and oligodendrocytes in response to glial activation or
injury and was recently studied as a potential serum
biomarker for traumatic brain injury, stroke, depression,
and blood brain barrier injury (Blyth et al. 2009; Schroeter
et al. 2013; Vos et al. 2004). S100B is also produced by
glia cells in PD associated neuroinflammation (Niranjan
2014). The role of S100B up-regulation in 6-OHDA-
treated LUHMES cells remains elusive, but may be in-
volved in the processes of neurite outgrowth and/or cyto-
protection as a part of the response to insults causing
neurite degeneration, as S100B was attributed as a neu-
rotropic factor (McAdory et al. 1998).
In conclusion for the first time, we presented a detailed
analysis of PD-related gene expression in LUHMES cells
treated with 6-OHDA and found out that the observed pro-
file of expression was not influenced by the lentiviral
overexpression of PGAM5 a protein recently implicated in
various processes related to the development of PD. We
believe that our results will be of help for researchers
working on PGAM5 and Parkinson’s Disease and that they
will encourage them to use LUHMES cells that are currently
emerging as a modern model for neurological disorders.
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